BRPI0408961A - método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente - Google Patents
método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um pacienteInfo
- Publication number
- BRPI0408961A BRPI0408961A BRPI0408961-8A BRPI0408961A BRPI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- determining
- condition
- erbb
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO PARA DETERMINAR UMA SITUAçãO DE DOENçA DE UM PACIENTE, MéTODO PARA SELECIONAR UM PACIENTE PARA TRATAMENTO DE UM CáNCER COM UM OU MAIS MEDICAMENTOS DE AçãO DIMéRICA DE ERBB, E, MéTODO PARA DETERMINAR UMA SITUAçãO CANCEROSA DE UM PACIENTE". A invenção está direcionada a uma nova classe de biomarcador em amostras de paciente que compreende dímeros de receptores de membrana de superfície celular de ErbB. Em um aspecto, a invenção inclui um método para determinar uma situação de uma doença ou condição saudável correlacionando-se tal condição com as quantidades de um ou mais dímeros de receptores de membrana de superfície celular de ErbB medidas diretamente em uma amostra do paciente, em particular uma amostra de tecido fixa. Em um outro aspecto, a invenção inclui um método para determinar uma situação de um câncer em um espécime de um indivíduo correlacionando-se medições de quantidades de um ou mais dímeros de receptores de membrana de superfície celular de ErbB nas células do espécime para tal situação, incluindo a presença ou ausência de um estado pré canceroso, presença ou ausência de um estado canceroso, prognóstico de um câncer ou responsividade ao tratamento. Preferivelmente, os métodos da invenção são implementados usando-se conjuntos de compostos de ligação tendo rótulos moleculares liberáveis que são específicos para componentes múltiplos de um ou mais tipos de dímeros receptores. Depois da ligação, os rótulos moleculares são liberados e separados da mistura de ensaio para análise.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45988803P | 2003-04-01 | 2003-04-01 | |
US10/623,057 US7105308B2 (en) | 2002-07-25 | 2003-07-17 | Detecting receptor oligomerization |
US49448203P | 2003-08-11 | 2003-08-11 | |
US50803403P | 2003-10-01 | 2003-10-01 | |
US51294103P | 2003-10-20 | 2003-10-20 | |
US52325803P | 2003-11-18 | 2003-11-18 | |
PCT/US2004/009715 WO2004091384A2 (en) | 2003-04-01 | 2004-03-30 | Erbb surface receptor complexes as biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0408961A true BRPI0408961A (pt) | 2006-10-31 |
Family
ID=33136354
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408961-8A BRPI0408961A (pt) | 2003-04-01 | 2004-03-30 | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente |
BRPI0408928-6A BRPI0408928A (pt) | 2003-04-01 | 2004-03-30 | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
BRPI0408950-2A BRPI0408950A (pt) | 2003-04-01 | 2004-03-30 | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408928-6A BRPI0408928A (pt) | 2003-04-01 | 2004-03-30 | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
BRPI0408950-2A BRPI0408950A (pt) | 2003-04-01 | 2004-03-30 | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP1613961A4 (pt) |
JP (2) | JP2006521821A (pt) |
AU (3) | AU2004230700A1 (pt) |
BR (3) | BRPI0408961A (pt) |
CA (3) | CA2521077A1 (pt) |
WO (3) | WO2004091384A2 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
AU2004230700A1 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
BRPI0413471A (pt) * | 2003-08-11 | 2006-10-17 | Monogram Biosciences Inc | métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica |
US7402399B2 (en) * | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
BRPI0515581A (pt) * | 2004-09-22 | 2008-07-29 | Tripath Imaging Inc | métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
CA2647843A1 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
CA2663595A1 (en) * | 2006-08-07 | 2008-02-14 | The Board Of Regents Of The University Of Texas System | Proteomic patterns of cancer prognostic and predictive signatures |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
AU2007324868B2 (en) | 2006-11-28 | 2014-03-20 | Daiichi Sankyo Europe Gmbh | Activated HER3 as a marker for predicting therapeutic efficacy |
PT2716301T (pt) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
CN101802618B (zh) * | 2007-07-13 | 2015-02-25 | 雀巢产品技术援助有限公司 | 利用基于抗体的阵列选择肺癌治疗药物 |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
US8168755B2 (en) * | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
UA104868C2 (uk) * | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
CN102439452B (zh) * | 2009-01-15 | 2015-04-15 | 美国控股实验室公司 | 通过测量her-2表达确定患者应答的方法 |
AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Biocept, Inc. | Devices and methods of cell capture and analysis |
US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
AU2010273319B2 (en) | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
PT3351558T (pt) | 2009-11-13 | 2020-04-09 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
US20140248291A1 (en) * | 2011-03-30 | 2014-09-04 | The Uab Research Foundation | Modulation of Cellular Migration |
KR101851425B1 (ko) * | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
EP2863920B1 (en) | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
US20160038503A1 (en) | 2012-11-21 | 2016-02-11 | David Richard | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
US20160041171A1 (en) * | 2013-04-05 | 2016-02-11 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
SG11201509367RA (en) * | 2013-05-21 | 2015-12-30 | Nestec Sa | Methods for predicting and improving the survival of colorectal cancer patients |
WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ, インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
WO2016115105A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
WO2016127220A1 (en) * | 2015-02-13 | 2016-08-18 | The University Of Queensland | Methods for classifying tumors and uses therefor |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
CN108780089B (zh) | 2016-03-15 | 2020-09-08 | 美国控股实验室公司 | 评估细胞间的蛋白质相互作用的方法 |
US20200355694A1 (en) * | 2017-11-20 | 2020-11-12 | Konica Minolta, Inc. | Drug Evaluation Method |
IT201800008274A1 (it) * | 2018-08-31 | 2020-03-02 | Alifax Srl | Metodo immunometrico per analisi cliniche biologiche |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
JP3464798B2 (ja) | 1992-07-31 | 2003-11-10 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 光活性化化学発光基質 |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
US6037134A (en) * | 1994-03-07 | 2000-03-14 | New York University Medical Center | Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes |
US5693271A (en) | 1994-09-01 | 1997-12-02 | Chase Industries, Inc. | Rotationally molding an insulated plastic molded door with integral hinge |
US5599631A (en) | 1995-03-08 | 1997-02-04 | Eastman Kodak Company | Fluorinated elastomer/fluorinated resin compositions for toner fusing members |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6095661A (en) | 1998-03-19 | 2000-08-01 | Ppt Vision, Inc. | Method and apparatus for an L.E.D. flashlight |
ES2252972T3 (es) * | 1998-09-08 | 2006-05-16 | Agouron Pharmaceuticals, Inc. | Modificaciones de la proteina vegfr-2 y procedimiento de uso. |
US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
JP4796259B2 (ja) | 2000-05-04 | 2011-10-19 | シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー | 複数のアナライトの検出において使用するための組成物 |
US6547654B2 (en) | 2000-07-22 | 2003-04-15 | Americo Del Raso | Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander |
WO2002068668A2 (en) * | 2001-02-22 | 2002-09-06 | Immunex Corporation | Compositions and methods for production cell culture |
EP1506399A2 (en) | 2001-05-21 | 2005-02-16 | Aclara BioSciences, Inc. | Methods and compositions for analyzing proteins |
WO2003006947A2 (en) | 2001-07-09 | 2003-01-23 | Aclara Biosciences, Inc. | Cell-screening assay and composition |
CA2354690A1 (en) | 2001-07-20 | 2001-10-27 | Jan Prinzmetal | Mat |
US6545102B1 (en) * | 2001-09-27 | 2003-04-08 | Lumigen, Inc. | Polymer-supported photosensitizers |
WO2003068808A1 (en) * | 2002-02-13 | 2003-08-21 | Garvan Institute Of Medical Research | Novel protein complexes and uses therefor |
US7910314B2 (en) * | 2002-03-01 | 2011-03-22 | Roger Williams Hospital | Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
AU2003222253A1 (en) | 2002-03-05 | 2003-09-22 | Monogram Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
KR20050025669A (ko) * | 2002-07-25 | 2005-03-14 | 아클라라 바이오사이언시스 인코퍼레이티드 | 수용체 올리고머화의 검출 |
AU2004230700A1 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
US7402399B2 (en) * | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
-
2004
- 2004-03-30 AU AU2004230700A patent/AU2004230700A1/en not_active Abandoned
- 2004-03-30 JP JP2006509481A patent/JP2006521821A/ja active Pending
- 2004-03-30 BR BRPI0408961-8A patent/BRPI0408961A/pt not_active IP Right Cessation
- 2004-03-30 AU AU2004225439A patent/AU2004225439A1/en not_active Abandoned
- 2004-03-30 EP EP04759065A patent/EP1613961A4/en not_active Withdrawn
- 2004-03-30 EP EP04759064.1A patent/EP1613205B1/en not_active Expired - Lifetime
- 2004-03-30 WO PCT/US2004/009715 patent/WO2004091384A2/en active Application Filing
- 2004-03-30 EP EP20040758577 patent/EP1613732A4/en not_active Withdrawn
- 2004-03-30 WO PCT/US2004/009717 patent/WO2004092353A2/en active Application Filing
- 2004-03-30 BR BRPI0408928-6A patent/BRPI0408928A/pt not_active IP Right Cessation
- 2004-03-30 AU AU2004229348A patent/AU2004229348A1/en not_active Abandoned
- 2004-03-30 CA CA002521077A patent/CA2521077A1/en not_active Abandoned
- 2004-03-30 CA CA002521106A patent/CA2521106A1/en not_active Abandoned
- 2004-03-30 CA CA002521082A patent/CA2521082A1/en not_active Abandoned
- 2004-03-30 WO PCT/US2004/009805 patent/WO2004087887A2/en active Application Filing
- 2004-03-30 BR BRPI0408950-2A patent/BRPI0408950A/pt not_active IP Right Cessation
- 2004-03-30 JP JP2006509479A patent/JP2006523314A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2004230700A1 (en) | 2004-10-28 |
CA2521106A1 (en) | 2004-10-14 |
EP1613732A2 (en) | 2006-01-11 |
AU2004225439A1 (en) | 2004-10-14 |
WO2004087887A2 (en) | 2004-10-14 |
CA2521077A1 (en) | 2004-10-28 |
WO2004087887A3 (en) | 2006-06-15 |
EP1613205B1 (en) | 2013-04-24 |
EP1613205A4 (en) | 2006-11-29 |
EP1613961A2 (en) | 2006-01-11 |
EP1613205A2 (en) | 2006-01-11 |
WO2004092353A3 (en) | 2005-03-03 |
BRPI0408950A (pt) | 2006-03-28 |
WO2004091384A3 (en) | 2005-12-29 |
EP1613961A4 (en) | 2007-03-07 |
CA2521082A1 (en) | 2004-10-28 |
WO2004092353A2 (en) | 2004-10-28 |
JP2006521821A (ja) | 2006-09-28 |
EP1613732A4 (en) | 2012-03-14 |
WO2004091384A2 (en) | 2004-10-28 |
BRPI0408928A (pt) | 2006-09-12 |
JP2006523314A (ja) | 2006-10-12 |
AU2004229348A1 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408961A (pt) | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente | |
Rice et al. | A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis | |
Figueiredo et al. | Genetic and epigenetic regulation of skeletal muscle ribosome biogenesis with exercise | |
Morabito et al. | Effects of genistein and hormone‐replacement therapy on bone loss in early postmenopausal women: a randomized double‐blind placebo‐controlled study | |
Cabral et al. | Mutations near amino end of α1 (I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing | |
Ukegawa et al. | Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells | |
van Oosterwijk et al. | Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets | |
Chen et al. | Heterodimerization of human orexin receptor 1 and kappa opioid receptor promotes protein kinase A/cAMP-response element binding protein signaling via a Gαs-mediated mechanism | |
Kazemi et al. | VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans | |
WO2006044748A3 (en) | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS | |
WO2005037071A3 (en) | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy | |
Bartsch et al. | Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size | |
Koizumi et al. | Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells | |
Roberts et al. | Mechanisms of mechanical overload-induced skeletal muscle hypertrophy: current understanding and future directions | |
BRPI0413471A (pt) | métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica | |
Ramage et al. | NMDA receptor expression and activity in osteoarthritic human articular chondrocytes | |
Nagano et al. | The inhibitory effect of soybean and soybean isoflavone diets on 2, 4-dinitrofluorobenzene-induced contact hypersensitivity in mice | |
Jun et al. | Expression of MET in alveolar soft part sarcoma | |
Lee et al. | Raftlin: a new biomarker in human sepsis | |
US7105292B2 (en) | Screening methods used to identify compounds that modulate a response of a cell to ultraviolet radiation exposure | |
US20230091848A1 (en) | Disease detection and treatment based on phenylacetyl glutamine levels | |
Beetch et al. | Subtle alterations in DNA methylation patterns in normal cells in response to dietary stilbenoids | |
WO2006044566A3 (en) | Autocrine growth factor receptors and methods | |
Rambow et al. | Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model | |
BR0209172A (pt) | Método de detecção de doenças induzidas por glúten em uma amostra sanguìnea de um indivìduo, e kit teste para uso no método |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 3A,4A,5A,6A E 7A ANUIDADE(S). |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |